Last reviewed: May 20, 2026 Last updated: May 20, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
A 2025 preclinical study in Cancer & Metabolism examined Retatrutide, also identified as LY3437943, in obesity-associated pancreatic cancer model systems
Lower prices often correlate with lower quality verification, making the cost savings potentially illusory if the product proves substandard
Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211)
Mayo Clinic
D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T